Disease · EFO_0004714
sexual dysfunction
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. sexual dysfunction. Diseases, record EFO_0004714. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004714
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs31
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BREMELANOTIDE ACETATE | CHEMBL4297533 | Protein | Approval | FDA | 1 | 0 | 0 | Drugs and targets |
| FLIBANSERIN | CHEMBL231068 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| TESTOSTERONE | CHEMBL386630 | Small molecule | Phase 3 | ClinicalTrials.gov | 18 | 18 | 17 | Drugs and targets |
| BREMELANOTIDE | CHEMBL2070241 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ESTRADIOL VALERATE | CHEMBL1511 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PRASTERONE | CHEMBL90593 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ESTROGEN | CHEMBL592868 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| LACTIC ACID | CHEMBL1200559 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SILDENAFIL | CHEMBL192 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TESTOSTERONE UNDECANOATE | CHEMBL2107067 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 31
See all 31 drugsTargets26
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ESR1 | Estrogen receptor | 4 | Estrogen receptor alpha agonist; Estrogen receptor modulator | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| MC4R | Melanocortin receptor 4 | 3 | Melanocortin receptor 4 agonist | Approval | https://conductscience.org/library/genes/4160 | Drugs and targets |
| AR | Androgen receptor | 2 | Androgen Receptor agonist | Phase 3 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/1268 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 2 | D2-like dopamine receptor agonist; Dopamine D2 receptor partial agonist | Phase 2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| ESR2 | Estrogen receptor | 2 | Estrogen receptor modulator | Phase 2 | https://conductscience.org/library/genes/2100 | Drugs and targets |
| HTR1A | 5-hydroxytryptamine receptor 1A | 2 | Serotonin 1a (5-HT1a) receptor partial agonist | Phase 2 | https://conductscience.org/library/genes/3350 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 2 | Serotonin 2a (5-HT2a) receptor antagonist | Unknown | https://conductscience.org/library/genes/3356 | Drugs and targets |
| ANGPT1 | Angiopoietin-1 | 1 | Angiopoietin-1 inhibitor | Preclinical | https://conductscience.org/library/genes/284 | Drugs and targets |
| ANGPT2 | Angiopoietin-2 | 1 | Angiopoietin-2 inhibitor | Preclinical | https://conductscience.org/library/genes/285 | Drugs and targets |
1 to 10 of 26
See all 26 targetsTrials44
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00467259 | Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women | Phase 3 | 1,271 | 2011-12-15 | Hypoactive Sexual Desire Disorder | TESTOSTERONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02333071 | 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | Phase 3 | 723 | 2020-12-23 | Hypoactive Sexual Desire Disorder | BREMELANOTIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02338960 | 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | Phase 3 | 714 | 2021-01-28 | Hypoactive Sexual Desire Disorder | BREMELANOTIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01382719 | Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder | Phase 2 | 612 | 2014-04-14 | Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder | BREMELANOTIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00981305 | Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors | Phase 3 | 136 | 2017-01-26 | Sexual Dysfunction, Breast Cancer Survivors | LACTIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT02593396 | Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men | Phase 2 | 80 | 2019-07-12 | Sexual Dysfunctions, Psychological, Hypoactive Sexual Desire Disorder, Erectile Dysfunctions | BUPROPION HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01338298 | Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia | Not applicable | 60 | 2018-05-16 | Hyperprolactinemia | ARIPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02865187 | Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction | Not applicable | 47 | 2021-10-07 | Female Sexual Dysfunction, Polycystic Ovary Syndrome | ERGOCALCIFEROL | Its record names the disease | ClinicalTrials.gov |
| NCT01455220 | The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis | Not applicable | 45 | 2017-03-31 | Multiple Sclerosis | NATALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00179517 | Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo | Phase 2 | 40 | 2017-08-08 | Seizure Disorder, Hypogonadism, Erectile Dysfunction | ANASTROZOLE, TESTOSTERONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 44
See all 44 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Testosterone vs Placebo: serious adverse events | 33 of 1,019 | 10 of 251 | 1,270 | NCT00467259 | Trial comparisons |
| Lactate-containing Vaginal Lubricant vs Placebo: serious adverse events | 0 of 50 | 0 of 57 | 107 | NCT00981305 | Trial comparisons |
| Active vs Placebo: deaths from any cause | 0 of 36 | 0 of 36 | 72 | NCT02593396 | Trial comparisons |
Active vs Placebo: Number of Participants With a Score of ≤2 (Much/Very Much Improved) on the Clinical Global Impression Scale Adapted for Sexual Function (CGI-SF) at Week 6 Between Placebo and Active Group | 21 of 36 | 10 of 36 | 72 | NCT02593396 | Trial comparisons |
| Active vs Placebo: serious adverse events | 0 of 36 | 0 of 36 | 72 | NCT02593396 | Trial comparisons |
| Vitamin D + Hormonal Contraception vs Vit D + Non-hormonal Contraception: Prevalence of Sexual Dysfunction in Women With PCOS | 26 of 33 | 11 of 14 | 47 | NCT02865187 | Trial comparisons |
| Aripiprazole vs Placebo: deaths from any cause | 0 of 20 | 0 of 18 | 38 | NCT01338298 | Trial comparisons |
| Aripiprazole vs Placebo: serious adverse events | 0 of 20 | 0 of 18 | 38 | NCT01338298 | Trial comparisons |
| Depotestosterone Plus Anastrozole (T-A) vs Depotestosterone Plus Placebo (T-P): deaths from any cause | 0 of 18 | 0 of 19 | 37 | NCT00179517 | Trial comparisons |
| Depotestosterone Plus Anastrozole (T-A) vs Depotestosterone Plus Placebo (T-P): serious adverse events | 0 of 18 | 0 of 19 | 37 | NCT00179517 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials52
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0004714
GET https://conductscience.org/api/diseases/v1/EFO_0004714/drugs?page=2